Clinical Trials

At Lehigh Valley Health Network, we are committed to providing our patients and community with the best possible care and treatments. Our research scientists are integrated with our clinical departments for a comprehensive, collaborative approach to research. Have a question about clinical trials? Contact the Network Office of Research and Innovation at 610-402-9543.

Showing 120 of 137 Clinical Trials

Clinical Research Trial

A081801 Lung Cancer

INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

A081801 Lung Cancer

INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

DCP-001

DCP-001, Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

APEC14B1

The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Clinical Research Trial

AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Clinical Research Trial

AALL1732

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Clinical Research Trial

AALL1732

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy